Co-Diagnostics, Inc.

CODX

OTC

Healthcare

Medical - Devices

Salt Lake City, UT, US132 employeesco-dx.com

$1.55

-0.07(-4.32%)

Mkt Cap $2M

$2.11

$248.31

52-Week Range

At a Glance

AI-generated

Revenue declined 84.1% to $622.5K as prior-year grant recognition ended, while operating loss widened 25.2% to -$50.2M from heavier impairments despite gross margin expansion to 64.3%.

Revenue breakdown: Grant (73.8%), Product (26.2%).

8-K

Co-Diagnostics reported a full year 2025 net loss of $46.9 million on $0.6 million revenue, driven by an $18.9 million impairment charge, and highlighted regulatory progress for its CoSara joint venture in India.

$2M

Market Cap

—

Revenue

—

Net Income

Employees132

Fundamentals

How The Business Makes Money

Revenue by Segment

Grant73.8%($7M)

Product26.2%($2M)

Revenue by Geography

US90.5%($8M)

Non Us9.5%($865.6K)

Activity

What Changed Recently

Delisting

Jan 12, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On January 7, 2026, Co-Diagnostics, Inc. (the “Company”) r

Financial Results

Mar 30, 2026

or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 19

Financial Results

Mar 9, 2026

by reference. Item 8.01. Other Events. Nasdaq Matters On March 9, 2026, Co-Diagnostics, Inc. (the “Company”) was formally notified by The Nasdaq Stock Market LL

Company Profile

CIK0001692415

ISINUS1897632048

CUSIP189763105

Phone801 438 1036

Address2401 S. Foothill Dr., Salt Lake City, UT, 84109, US

SEC EDGAR